4th Cannabinoid Derived Pharmaceuticals Summit - September 2021 - Boston

Pioneering the Development of Cannabinoid Pharmaceuticals Across the World
Cannabinoids are some of the most well-known and widely accessed medicinal compounds in the world, with known applications in dozens of conditions and potentially many more. The remarkable success of cannabinoids being approved for use in paediatric epilepsy was just the beginning.

The Cannabinoid Derived Pharmaceuticals Summit is the world’s largest conference devoted exclusively to the production of CDPs for medical conditions using FDA/EMA approval pathways, with a focus on clinical trial design and commercialization, target biology and pharmacology, GMP-compliant product formulation, drug delivery, and managing the changing regulatory environment (particularly in light of new policies from the US government administration).

Website https://go.evvnt.com/769702-0?pid=176 
Tickets https://go.evvnt.com/769702-2?pid=176 
Brochure https://go.evvnt.com/769702-3?pid=176 

Prices:
Conference + 2 Workshops USD 3397.00,
Conference + 1 Workshop USD 2948.00,
Conference Only USD 2499.00

Speakers: Monica Taing, Board Member, ACHEM, Tomas Skrinskas, Principal & Founder, Ascension Sciences, Oren Giladi, Head of Pharmaceutical Development, BOL Pharma, Eyal Barad, Co-Founder & Chief Executive Officer, Cannabics Pharmaceuticals, Sud Agarwal, Chief Executive Officer, Cannvalate, Hunter Land, Senior Scientific Director, Canopy Growth Corp, Loren DeFalco, Partner, CB1 Capital, Clifton Flack, Founder, CIITECH, Erich Veitenheimer, Partner, Cooley LLP, Daniel Knauss, Partner, Cooley LLP, Marcelo Pomeranz, Associate, Cooley LLP, Mikael Sodergren, Research Director & Managing Director, EMMAC Life Science & Sapphire Medical Clinics, David Traylor, Senior Director – Managing, Golden Eagle Partners, Alice Mead, Vice President - Public Policy, Greenwich Biosciences, Robert Jappie, Partner, Ince & Co, Michael Woudenberg, Vice President of Commercialisation, InMed Pharmaceuticals Ltd, Frank Rice, President & Chief Scientist, Intidyn, Howard Goodwin, Managing Partner, Intrinsic Capital Partners, Ryan Gregory Vandrey, Professor - Psychiatry & Behavioral Sciences, Johns Hopkins School of Medicine, Guillermo Moreno, Sanz Scientific and Medical Director, Khiron Life Sciences Corp., Giovanni Isoldi, Chief Technology Officer, Materia Medica Processing Srl, Nicolas Pateras, Managing Director, Materia Ventures, Nadiya Lisdover, Chief Regulatory Officer, MGC Pharmaceuticals Ltd, Valentino Parravicini, Chief Scientific Officer, Oxford Cannabinoid Technologies, Marsha R. Rosner, Professor, Ben May Dept. for Cancer Research Gordon Center for Integrative Sciences, University of Chicago, Con Stough, Professor Swinburne University, Gregory Sotzing Professor – Chemistry, University of Connecticut, Emmanuel Onaivi, Professor, William Paterson University, Oludare Odumosu, Chief Executive Officer, Zelira Therapeutics, Jay Blankenship, Vice President, Zylo Therapeutics, Brian Murphy, Chief Executive Officer, Somme Therapeutics, Karolina Urban, Vice President of Medical Programs, Avicanna, Mark Rosenfeld, Chief Executive Officer & Chief Science Officer, Ananda Scientific

Time: On Tuesday September 21, 2021 at 9:00 am (ends Thursday September 23, 2021 at 6:30 pm)

Venue details: Aloft Boston Seaport District